Clinical Trials Logo

Fibrosis Lung clinical trials

View clinical trials related to Fibrosis Lung.

Filter by:
  • Completed  
  • Page 1

NCT ID: NCT05227443 Completed - Lung Diseases Clinical Trials

Effects of Exercise Training on Respiratory Performance in Patients With Fibrosing Interstitial Lung Diseases

ET-fILD
Start date: January 16, 2020
Phase: N/A
Study type: Interventional

The current study recruited patients with fibrosing interstitial lung diseases (f-ILD) whatever was the underlying pathology. The investigators aimed to compare the effects of aerobic exercises for lower limbs (LL) versus upper limbs, lower limbs, and breathing exercises (ULB) on the peak exercise measurements that was measured using cardiopulmonary exercise testing (CPET), dyspnea and health related quality of life assessment in this group of patients.

NCT ID: NCT04527354 Completed - Clinical trials for SARS-CoV-2 Infection

Pilot Study to Assess Efficacy and Safety of Treamid in the Rehabilitation of Patients After COVID-19 Pneumonia

Start date: September 1, 2020
Phase: Phase 2
Study type: Interventional

The innovative drug Treamid is planned for use in the rehabilitation of patients after COVID-19 pneumonia in a pilot, multicenter, randomized, double-blind, placebo-controlled Phase II clinical study to assess the efficacy and safety of Treamid, tablets, 50 mg in patients with fibrotic changes in the lungs after COVID-19 pneumonia during a 28-day treatment. The primary objective of the study is to demonstrate the efficacy of Treamid tablet, 50 mg in change in forced vital capacity (FVC) and/or diffusing capacity of lung for carbon monoxide (DLCO) at Week 4. The secondary objective of the study is to evaluate the safety of Treamid tablet, 50 mg and pharmacokinetics (PK).

NCT ID: NCT03438032 Completed - Systemic Sclerosis Clinical Trials

Identifying Unique Pathogenic Macrophages in Systemic Sclerosis-ILD

Start date: June 28, 2018
Phase:
Study type: Observational

Alveolar macrophages isolated from bronchoalveolar lavage (BAL) fluid from systemic sclerosis (SSc) patients with clinically significant lung fibrosis will be studied at baseline and at 6 months after enrollment to assess longitudinally the presence and persistence of an emergent, pro-fibrotic alveolar macrophage population, using single cell RNA-Seq technology to measure the individual transcriptome from each cell.